½ÃÀ庸°í¼­
»óǰÄÚµå
1513929

¼¼°èÀÇ Àΰ£ »ý½Ä ±â¼ú ½ÃÀå

Human Reproductive Technologies

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Industry Analysts, Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 167 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àΰ£ »ý½Ä ±â¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 346¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»ó

2023³â¿¡ 296¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Àΰ£ »ý½Ä±â¼ú ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£¿¡¼­ CAGR 2.3%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 346¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÇÀÓ¾à ¹× ÀåÄ¡´Â CAGR 2.6%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 220¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÒÀÓ Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 80¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àΰ£ »ý½Ä±â¼ú ½ÃÀåÀº 2023³â 80¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 66¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 3.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.3%¿Í 2.0%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àΰ£ »ý½Ä ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à

Àΰ£ »ý½Ä±â¼ú ½ÃÀåÀº Àα¸µ¿ÅÂÀÇ º¯È­, ±â¼úÀÇ Áøº¸, »çȸ±Ô¹üÀÇ ÁøÈ­°¡ °ãÃÄ Å« ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡´Â ºÒÀÓ·ü »ó½Â°ú °¡Á·°èȹ ÈıâÈ­ÀÇ Ãß¼¼ º¯È­·Î ÀÎÇØ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ºÒÀÓ°ú »ý½Ä¿¡ °üÇÑ °úÁ¦¸¦ ´Ù·ç±â À§ÇÑ ´Ù¾çÇÑ Ä¡·á¿Í ±â¼úÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­, Ãâ»êÀÇ Áö¿¬, »ý½Ä ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹°ÁúÀÇ ¼Òºñ·® Áõ°¡ µîÀÇ ¿äÀÎÀÌ ºÒÀÓÀÇ ¸¸¿¬À» Á¶ÀåÇϰí, »ý½Ä ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÇÇÐÀÇ Áøº¸·Î ÀÌ·¯ÇÑ ±â¼úÀº º¸´Ù ÀÌ¿ëÇϱ⠽±°í È¿°úÀûÀÎ °ÍÀÌ µÇ¾î, ¼¼°è¿¡¼­ ä¿ëÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷, °æ±¸ ÇÇÀÓ¾àÀº »ç¿ëÇϱ⠽±°í, ³Î¸® ÀÌ¿ë °¡´ÉÇϸç, Åõ¿©µµ °£´ÜÇϱ⠶§¹®¿¡ ÇÇÀÓ¾à ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ¾î, °Ô´Ù°¡, °èȹ¿ÜÀÇ ÀÓ½ÅÀ» ¸·¾Æ, ¼ºÀÇ °Ç°­À» ÃËÁøÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÇÇØ Áö¿øµË´Ï´Ù.

ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ̶ó´Â Á¡¿¡¼­ ü¿Ü¼öÁ¤(IVF)°ú °°Àº »ý½Äº¸Á¶ÀÇ·á±â¼ú(ART)ÀÌ ÇöÀúÇÑ ¹ßÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÁöÀûÀç»ê(IP)À» ART¿¡ ÅëÇÕ, ƯÈ÷ ü¿Ü ¹è¿ìÀÚ Çü¼º(IVG)°ú °°Àº ½Å±â¼úÀº »óȲÀ» Å©°Ô ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ¼¼Æ÷¸¦ ÀçÇÁ·Î±×·¡¹ÖÇÏ¿© Á¤ÀÚ³ª ³­ÀÚ·Î ¼ºÀå½ÃŰ´Â IVG´Â ±âÁ¸¿¡´Â ½ÇÇöÇÒ ¼ö ¾ø¾ú´ø À¯ÀüÀÚÀÇ ¼±ÅÃÀ̳ª º¯°æÀ» °¡´ÉÇÏ°Ô ÇÒ ¼ö ÀÖ¾î, Á¾·¡ÀÇ ¹æ¹ýÀ¸·ÎºÎÅÍÀÇ Å« ÀüȯÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÁöÀû Àç»ê¿¡ ´ëÇÑ Á¢±ÙÀº °øµ¿ÀûÀÌ°í °³¹æÀûÀÎ °øÀ¯ ¸ðµ¨¿¡¼­ º¸´Ù °æÀïÀûÀÎ °ÍÀ¸·Î ÁøÈ­Çϰí ÀÖÀ¸¸ç, ¿¬±¸ÀÚ¿Í ±â¾÷Àº ƯÇãÀÇ È®º¸¸¦ Á¡Á¡ ´õ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ º¯È­´Â IVGÀÇ Å« °æÁ¦Àû ÀáÀç·Â¿¡ ¿µÇâÀ» ¹Þ¾ÒÁö¸¸ »ý½Ä ±â¼ú¿¡¼­ ƯÇãÀÇ ´ë»óÀÌ µÉ ¼öÀÖ´Â ¹°ÁúÀÇ ¹üÀ§¿Í ½ÇÇà °¡´É¼º¿¡ ¿µÇâÀ» ÁÙ ¼öÀÖ´Â º¹ÀâÇÑ À±¸®Àû ¹× ±ÔÁ¦Àû °úÁ¦µµ °¡Á®¿É´Ï´Ù.

Àΰ£ »ý½Ä ±â¼ú ½ÃÀåÀÇ È®´ë´Â ¸î °¡Áö ÁÖ¿ä ÃËÁø¿äÀο¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ³­¼¼Æ÷Áú³» Á¤ÀÚÁÖÀÔ¹ý(ICSI)°ú Âø»óÀü À¯ÀüÀÚÁø´Ü¹ý(PGD) µîÀÇ ±â¼ú Çõ½ÅÀº ºÒÀÓÄ¡·á¿¡ Çõ¸íÀ» °¡Á®¿À°í, ±× È¿´ÉÀ» ³ô¿© ¸Å·ÂÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ART°¡ »çȸÀûÀ¸·Î ¹Þ¾Æµé¿©Áö¸é¼­ ½ºÆ¼±×¸¶(Æí°ß)°¡ °¨¼ÒÇϰí, ƯÈ÷ ¼±ÅÃÀûÀÎ ÇÑ ºÎ¸ð³ª LGBTQ °¡Á· µî ´Ù¾çÇÑ °¡Á· ±¸¼º °£ÀÇ ÀÌ¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ÀÇ·á ´ëÃâ ¼±ÅÃÀÇ È®´ë, »ó¾÷ ÅõÀÚ Áõ°¡, ÁöÁöÀûÀÎ ¹ý °³Á¤¿¡ ÀÇÇØ ÀÌ·¯ÇÑ ±â¼úÀº º¸´Ù ÀÌ¿ëÇϱ⠽¬¿ö º¸±ÞµÇ¾ú½À´Ï´Ù. °Ô´Ù°¡, À¯ÀüÀÚ ½ºÅ©¸®´×ÀÇ Áøº¸¿Í °³ÀÎÈ­µÈ ÀÇ·á µ¿ÇâÀº ´õ¿í ¸ÂÃãÈ­µÇ°í È¿°úÀûÀÎ ºÒÀÓ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ÇÔ²² »ý½Ä±â¼úÀÌ ´Ü¼øÈ÷ ´É·ÂÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó »çȸÀÇ Æ²°ú ±â´ë¿¡ ÅëÇյǰí ÀÖ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåȯ°æÀÌ ¾ç¼ºµÇ¾î ¹Ì·¡ ¼¼´ë°¡ ¾î¶»°Ô Àӽš¤Ãâ»êµÉ °ÍÀΰ¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 12»ç)

  • Ansell Healthcare LLC
  • Ansell Ltd.
  • Apothecus Pharmaceutical Corporation
  • Bayer AG
  • Cipla Ltd.
  • Ferring Pharmaceuticals, Inc.
  • Indian Drugs & Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Mapa GmbH
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer, Inc.
  • The Female Health Company(FC2)
  • T-MARC Tanzania

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä
  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
  • ¼¼°è ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ºÐ¼®

  • ¹Ì±¹
  • ij³ª´Ù
  • ÀϺ»
  • Áß±¹
  • À¯·´
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • È£ÁÖ
  • Àεµ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • À̶õ
  • À̽º¶ó¿¤
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦4Àå °æÀï

JHS 24.07.24

Global Human Reproductive Technologies Market to Reach US$34.6 Billion by 2030

The global market for Human Reproductive Technologies estimated at US$29.6 Billion in the year 2023, is expected to reach US$34.6 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2023-2030. Contraceptive Drugs & Devices, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$22.0 Billion by the end of the analysis period. Growth in the Infertility Treatment segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 3.9% CAGR

The Human Reproductive Technologies market in the U.S. is estimated at US$8.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 3.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Human Reproductive Technologies Market - Key Trends and Drivers Summarized

The human reproductive technologies market is experiencing substantial growth due to a confluence of demographic shifts, technological advancements, and evolving societal norms. This sector includes a variety of treatments and technologies designed to address fertility and reproduction challenges, with increasing demand driven by higher infertility rates and shifting trends towards later family planning. Factors such as lifestyle changes, delayed childbearing, and higher consumption of substances affecting fertility contribute to the growing prevalence of infertility, prompting greater reliance on reproductive technologies. Medical advancements are making these technologies more accessible and effective, enhancing their adoption across the globe. In particular, the contraceptive segment holds a significant market share due to the ease of use, widespread availability, and simple administration of oral contraceptives, further supported by government initiatives aimed at preventing unplanned pregnancies and promoting sexual health.

In terms of technological innovation within this sector, assistive reproductive technologies (ART) like in vitro fertilization (IVF) have seen notable developments. The integration of intellectual property (IP) into ART, especially with emerging technologies such as in vitro gametogenesis (IVG), is reshaping the landscape. IVG, which involves reprogramming cells to develop into sperm or eggs, represents a significant shift from traditional methods by potentially allowing genetic selection and modification previously unattainable. The approach to IP in this realm has evolved from a collaborative, open-sharing model to a more competitive one, with researchers and companies increasingly seeking to secure patents. This shift is influenced by the substantial financial potential of IVG, although it also brings complex ethical and regulatory challenges that could affect the scope and viability of patentable material in reproductive technologies.

The expansion of the human reproductive technologies market is propelled by several key drivers. Innovations such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD) continue to revolutionize fertility treatments, enhancing their effectiveness and broadening their appeal. The growing societal acceptance of ART has reduced stigma and increased usage, particularly among diverse family structures, including single parents by choice and LGBTQ+ families. Additionally, the expansion of healthcare financing options, increased commercial investments, and supportive legislative changes have made these technologies more accessible and popular. Moreover, advancements in genetic screening and the trend toward personalized medicine are enabling more tailored and effective fertility treatments. Collectively, these factors are fostering a dynamic market environment where reproductive technologies are not only advancing in capability but also becoming more integrated into societal frameworks and expectations, significantly impacting how future generations are conceived and born.

Select Competitors (Total 12 Featured) -

  • Ansell Healthcare LLC
  • Ansell Ltd.
  • Apothecus Pharmaceutical Corporation
  • Bayer AG
  • Cipla Ltd.
  • Ferring Pharmaceuticals, Inc.
  • Indian Drugs & Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Mapa GmbH
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer, Inc.
  • The Female Health Company (FC2)
  • T-MARC Tanzania

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Human Reproductive Technologies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Infertility Rates Propel Growth for Human Reproductive Technologies
    • Advancements in Assisted Reproductive Technology (ART) Expands Addressable Market Opportunity
    • Increasing Awareness and Acceptance of IVF Throws the Spotlight on Market Growth
    • Technological Innovations in Cryopreservation Drives Demand for Fertility Preservation
    • Regenerative Medicine and Stem Cell Research Strengthens Business Case for Novel Therapies
    • Genetic Screening and Diagnostic Innovations Generate Accelerated Demand
    • Here's the Story on the Market Impact Rising Age of First-Time Parenthood
    • Improved Success Rates of Fertility Treatments Sustains Growth in the Market
    • Telemedicine Integration Drives Adoption of Reproductive Health Services
    • Regulatory Approvals and Ethical Issues Impact Market Dynamics
    • Here's How Personalized Medicine and Precision Fertility Enhance Treatment Efficacy
    • Advancements in Non-Invasive Diagnostic Techniques Drives Market Adoption
    • Environmental and Occupational Factors Propel Growth in Fertility Solutions Market
    • Increasing Focus on Male Infertility Solutions Expands Market Opportunity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Human Reproductive Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Contraceptive Drugs & Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Contraceptive Drugs & Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Contraceptive Drugs & Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Infertility Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Infertility Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Infertility Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Human Reproductive Technologies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • JAPAN
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • CHINA
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • EUROPE
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • FRANCE
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • GERMANY
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Human Reproductive Technologies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • INDIA
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Human Reproductive Technologies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Human Reproductive Technologies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030
  • AFRICA
    • Human Reproductive Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Human Reproductive Technologies by Technology - Contraceptive Drugs & Devices and Infertility Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive Drugs & Devices and Infertility Treatment for the Years 2014, 2024 & 2030

IV. COMPETITION

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦